Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Leukemia, Myelomonocytic, Chronic 1

Interventions

Decitabine 3decitabine and cedazuridine drug combination 2cedazuridine 2Cytarabine 2Azacitidine 2treosulfan 1olutasidenib 1luspatercept 1ivosidenib 1imetelstat 1glasdegib 1enasidenib 1GRN163L peptide 1Daunorubicin 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Myelodysplastic Syndromes × decitabine and cedazuridine drug combination × Clear all
NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
130 enrolled 34 charts 1 FDA
Myeloid

Myelodysplastic Syndromes

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡